胶质瘤中IGF-1和IGFBP-3的表达及临床意义研究  

Research of expression and clinical significance of IGF-1 and IGFBP-3 in glioma

作　　者：叶昀[1,2] 牛朝诗 杨洋 李冬雪 鲍得俊 范振 

机构地区：[1]安徽医科大学附属省立医院神经外科、脑功能与脑疾病安徽省重点实验室、安徽省脑立体定向神经外科研究所,合肥230001 [2]舒城县人民医院神经外科,舒城231300

出　　处：《安徽医科大学学报》2016年第2期231-234,共4页Acta Universitatis Medicinalis Anhui

基　　金：安徽省重点实验室绩效考核补助项目(编号:1306c083028)

摘　　要：目的检测胰岛素样生长因子-1(IGF-1)和胰岛素样生长因子结合蛋白-3(IGFBP-3)在胶质瘤患者术前、术后外周血血清中的含量及变化和胶质瘤组织局部的表达情况,探讨发生发展的关系及其在辅助诊断、危险性预测和治疗中的临床意义。方法运用化学发光法检测胶质瘤组和对照组患者术前、术后外周血血清中IGF-1、IGFBP-3的水平;正常脑组织(颅脑损伤手术时的脑组织)和肿瘤组织行IGF-1、IGFBP-3免疫组化染色检查,显微镜下观察免疫组化染色结果。结果对照组血清中IGF-1及IGFBP-3术前及术后无明显变化,差异无统计学意义;而胶质瘤患者血清中IGF-1及IGFBP-3表达水平在术后较术前均明显下降(P<0.05)。无论术前术后,IGF-1和IGFBP-3在不同级别胶质瘤患者的血清学表达与级别无显著相关性。胶质瘤组织中,IGF-1表达水平显著提高(P<0.05),IGFBP-3在胶质瘤中的表达亦高于对照组(P<0.05)。胶质瘤级别越高,胶质瘤组织中IGF-1和IGFBP-3的表达越高,与病理级别呈正相关(P<0.01)。结论 IGF-1和IGFBP-3可能在促进胶质瘤的发生、发展有重要作用,检测其水平变化对胶质瘤的诊断、判断预后有重要意义。Objective To explore the exact roles of IGF-1 and IGFBP-3 in the development of glioma and analyze their clinical significance in auxiliary diagnosis, risk prediction and therapy. Methods Chemiluminescence method was used to detect the contents and their change of IGF-1 and IGFBP-3 in serum of glioma group and control group pre and post operation. Immunohistochemistry was used to detect the expressions of IGF-1 and IGFBP-3 in glioma tissues and normal brain tissues. Results Compared to pre operation, the post operation contents of IGF-1 and IGFBP-3 in glioma group significantly decreased （P 〈 0. 05 ）, while the data of the control group had no obvious difference. No matter pre or post operation, the expressions of IGF-1 and IGFBP-3 in serum were irrelevant to the pathologic gradation of glioma. The expressions of IGF-1 and IGFBP-3 significantly increased （ P 〈0. 05 ） and were positively correlated with the pathologic gradation （P 〈 0. 01 ）. Conclusion IGF-1 and IGFBP-3 might promote the development of glioma and detect the contents and their changes have important value in the diagnosis and prognosis.

关 键 词：胶质瘤 胰岛素样生长因子-1 胰岛素样生长因子结合蛋白-3 

分 类 号：R739.41[医药卫生—肿瘤]